https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-price-target-lowered-to-460-from-550-at-truist Benchmark analyst Bruce Jackson raised the firm’s price ...

Horrible, I know! How can I get through my day without my aromatic leaf water? Vobaga Coffee Mug Warmer: was $25 now $22 at Amazon Nothing beats a warm cup of coffee or tea, so why not let it stay ...

Humacyte has a 52 week low of $2.48 and a 52 week high of $9.97. The stock has a market cap of $583.99 million, a PE ratio of -3.46 and a beta of 1.38. The business has a 50 day moving average of ...

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has been assigned an average recommendation of “Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports.

STORY HIGHLIGHTS FDA approved Humacyte's Symvess for vascular trauma treatment. Symvess is a bioengineered human tissue vascular conduit. Humacyte plans commercial launch and technology expansion.

Financial giants have made a conspicuous bearish move on Humacyte. Our analysis of options history for Humacyte (NASDAQ:HUMA) revealed 9 unusual trades. Delving into the details, we found 11% of ...

On Thursday, H.C. Wainwright adjusted its financial outlook for shares of Humacyte (NASDAQ: HUMA), increasing the price target to $15.00 from the previous $12.00 while reaffirming a Buy rating.

Humacyte (NASDAQ:HUMA) shares climbed ~57% in the premarket on Friday after the bioengineered tissue maker announced the FDA approval of Symvess, an off-the-shelf, implantable vascular conduit ...

FDA approves Humacyte's Symvess for urgent vascular repair in extremity arterial injuries when autologous grafts aren't feasible. Symvess provides off-the-shelf bioengineered vascular conduits ...